Status:
COMPLETED
Population Pharmacokinetics of Linezolid
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Methicillin-Resistant Staphylococcus AureuS
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Linezolid is the first of a new class of antibacterial drugs, the oxazolidinones. It has a specific inhibitory activity against Gram positive bacteria, including methicillin-resistant Staphylococcus a...
Detailed Description
The demographic, clinical and biological parameters are collected. Patients receive Linezolid as 600 mg twice a day during an administration of 60 minutes. Blood sampling are collected on the second ...
Eligibility Criteria
Inclusion
- In-patient stay in intensive care
- Over 18 years old
- Presenting with MRSA nosocomial pneumonia or bacteraemia with a strain thought to be sensitive to Linezolid
- Simplified Acute Physiological Score (SAPS) II \> 20
- Expected duration of life \> 7 days.
Exclusion
- History of allergy to linezolid or any of the antibiotics used
- Isolation of MRSA resistant to linezolid
- Lack of seeds
- Pregnancy and lactation
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01200654
Start Date
November 1 2007
End Date
August 1 2010
Last Update
October 23 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.